once-weekly basal insulin

Once-weekly basal insulin refers to a class of long-acting insulin analogs designed for subcutaneous administration once every seven days, primarily for the management of type 1 and type 2 diabetes. These agents, such as insulin icodec and insulin efsitora alfa, utilize various molecular modifications—such as fatty acid acylation or fusion to immunoglobulin Fc fragments—to extend their pharmacokinetic half-life and provide a steady glucose-lowering effect over a full week. By reducing the injection frequency from daily to weekly, these therapies aim to reduce treatment burden, improve patient adherence, and address psychological insulin resistance, potentially leading to earlier initiation of insulin therapy and better long-term glycemic control.

Other names

once-weekly basal insulinweekly insulinonce-weekly insulin